Pedro L Moro1, Yenlik Zheteyeva2, Faith Barash3, Paige Lewis4, Maria Cano4. 1. Immunization Safety Office (ISO), Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Centers for Disease Control and Prevention (CDC), United States. Electronic address: plmoro@yahoo.com. 2. Community Interventions for Infection Control Unit, Division of Global Migration and Quarantine, NCEZID, CDC, United States. 3. Center for Biologics Evaluation and Research, Food and Drug Administration (FDA), United States. 4. Immunization Safety Office (ISO), Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Centers for Disease Control and Prevention (CDC), United States.
Abstract
BACKGROUND: The safety of hepatitis B vaccination during pregnancy has not been well studied. OBJECTIVE: We characterized adverse events (AEs) after hepatitis B vaccination of pregnant women reported to the Vaccine Adverse Event Reporting System (VAERS), a spontaneous reporting surveillance system. METHODS: We searched VAERS for AEs reports involving pregnant women who received hepatitis B vaccine from January 1, 1990-June 30, 2016. All reports and available medical records were reviewed by physicians. Observed AEs were compared to expected AEs and known rates of pregnancy outcomes to assess for any unexpected safety concern. RESULTS: We found 192 reports involving pregnant women following hepatitis B vaccination of which 110 (57.3%) described AEs; 12 (6.3%) were classified as serious; one newborn death was identified in a severely premature delivery, and there were no maternal deaths. Eighty-two (42.7%) reports did not describe any AEs. Among pregnancies for which gestational age was reported, most women were vaccinated during the first trimester, 86/115 (74.7%). Among reports describing an AE, the most common pregnancy-specific outcomes included spontaneous abortion in 23 reports, preterm delivery in 7 reports, and elective termination in 5 reports. The most common non-pregnancy specific outcomes were general disorders and administration site conditions, such as injection site and systemic reactions, in 21 reports. Among 22 reports describing an AE among infants born to women vaccinated during pregnancy, 5 described major birth defects each affecting different organ systems. CONCLUSION: Our analysis of VAERS reports involving hepatitis B vaccination during pregnancy did not identify any new or unexpected safety concerns. Published by Elsevier Ltd.
BACKGROUND: The safety of hepatitis B vaccination during pregnancy has not been well studied. OBJECTIVE: We characterized adverse events (AEs) after hepatitis B vaccination of pregnant women reported to the Vaccine Adverse Event Reporting System (VAERS), a spontaneous reporting surveillance system. METHODS: We searched VAERS for AEs reports involving pregnant women who received hepatitis B vaccine from January 1, 1990-June 30, 2016. All reports and available medical records were reviewed by physicians. Observed AEs were compared to expected AEs and known rates of pregnancy outcomes to assess for any unexpected safety concern. RESULTS: We found 192 reports involving pregnant women following hepatitis B vaccination of which 110 (57.3%) described AEs; 12 (6.3%) were classified as serious; one newborn death was identified in a severely premature delivery, and there were no maternal deaths. Eighty-two (42.7%) reports did not describe any AEs. Among pregnancies for which gestational age was reported, most women were vaccinated during the first trimester, 86/115 (74.7%). Among reports describing an AE, the most common pregnancy-specific outcomes included spontaneous abortion in 23 reports, preterm delivery in 7 reports, and elective termination in 5 reports. The most common non-pregnancy specific outcomes were general disorders and administration site conditions, such as injection site and systemic reactions, in 21 reports. Among 22 reports describing an AE among infants born to women vaccinated during pregnancy, 5 described major birth defects each affecting different organ systems. CONCLUSION: Our analysis of VAERS reports involving hepatitis B vaccination during pregnancy did not identify any new or unexpected safety concerns. Published by Elsevier Ltd.
Entities:
Keywords:
Adverse event; Epidemiology; Hepatitis B vaccine; Surveillance; Vaccine safety
Authors: Yenlik A Zheteyeva; Pedro L Moro; Naomi K Tepper; Sonja A Rasmussen; Faith E Barash; Natalia V Revzina; Dmitry Kissin; Paige W Lewis; Xin Yue; Penina Haber; Jerome I Tokars; Claudia Vellozzi; Karen R Broder Journal: Am J Obstet Gynecol Date: 2012-05-14 Impact factor: 8.661
Authors: Eric E Mast; Harold S Margolis; Anthony E Fiore; Edward W Brink; Susan T Goldstein; Susan A Wang; Linda A Moyer; Beth P Bell; Miriam J Alter Journal: MMWR Recomm Rep Date: 2005-12-23
Authors: Eric E Mast; Cindy M Weinbaum; Anthony E Fiore; Miriam J Alter; Beth P Bell; Lyn Finelli; Lance E Rodewald; John M Douglas; Robert S Janssen; John W Ward Journal: MMWR Recomm Rep Date: 2006-12-08
Authors: Allison L Naleway; Samantha Kurosky; Michelle L Henninger; Rachel Gold; James D Nordin; Elyse O Kharbanda; Stephanie Irving; T Craig Cheetham; Cynthia Nakasato; Jason M Glanz; Simon J Hambidge; Robert L Davis; Nicola P Klein; Natalie L McCarthy; Eric Weintraub Journal: Am J Prev Med Date: 2014-02 Impact factor: 5.043
Authors: Steven Black; Juhani Eskola; Claire-Anne Siegrist; Neal Halsey; Noni MacDonald; Barbara Law; Elizabeth Miller; Nick Andrews; Julia Stowe; Daniel Salmon; Kirsten Vannice; Hector S Izurieta; Aysha Akhtar; Mike Gold; Gabriel Oselka; Patrick Zuber; Dina Pfeifer; Claudia Vellozzi Journal: Lancet Date: 2009-10-31 Impact factor: 79.321
Authors: Agustín Ciapponi; Ariel Bardach; Agustina Mazzoni; Tomás Alconada; Steven A Anderson; Fernando J Argento; Jamile Ballivian; Karin Bok; Daniel Comandé; Emily Erbelding; Erin Goucher; Beate Kampmann; Ruth Karron; Flor M Munoz; María Carolina Palermo; Edward P K Parker; Federico Rodriguez Cairoli; Victoria Santa María; Andy S Stergachis; Gerald Voss; Xu Xiong; Natalia Zamora; Sabra Zaraa; Mabel Berrueta; Pierre M Buekens Journal: Vaccine Date: 2021-08-13 Impact factor: 3.641
Authors: Isabela Oliveira da Silveira; Thales Philipe Rodrigues da Silva; Bianca Maria Oliveira Luvisaro; Roberta Barros da Silva; Josianne Dias Gusmão; Aline Mendes Vimieiro; Valéria Conceição de Oliveira; Karina Cristina Rouwe de Souza; Ana Paula Vieira Faria; Fernanda Penido Matozinhos Journal: Rev Saude Publica Date: 2021-05-17 Impact factor: 2.772
Authors: Agustín Ciapponi; Ariel Bardach; Agustina Mazzoni; Tomás Alconada; Steven Anderson; Fernando J Argento; Jamile Ballivian; Karin Bok; Daniel Comandé; Emily Erbelding; Erin Goucher; Beate Kampmann; Ruth Karron; Flor M Munoz; María Carolina Palermo; Edward P K Parker; Federico Rodriguez Cairoli; María Victoria Santa; Andy Stergachis; Gerald Voss; Xu Xiong; Natalia Zamora; Sabra Zaraa; Mabel Berrueta; Pierre M Buekens Journal: medRxiv Date: 2021-06-06